Patient and Donor Characteristics
| Characteristic . | Busulfan . | TBI . |
|---|---|---|
| No. of patients | 88 | 79 |
| Recipient age (yr) | ||
| Median | 35 | 34 |
| Range | 2-55 | 1-53 |
| Donor age (yr) | ||
| Median | 35 | 34 |
| Range | 4-62 | 2-68 |
| HLA-identical siblings (n) | 87 | 79 |
| HLA-identical parents (n) | 1 | 0 |
| Marrow cell dose (×107/kg) | ||
| Median | 26 | 26 |
| Range | 3-57 | 3-58 |
| Diagnosis (n) | ||
| AML | ||
| First remission | 25 | 26 |
| Second or later remission, early relapse* | 12 | 6 |
| ALL | ||
| First remission | 11 | 11 |
| Second or later remission | 7 | 9 |
| CML | ||
| First chronic phase | 22 | 24 |
| Second, accelerated phase | 7 | 2 |
| Blast crisis | 1 | 1 |
| Lymphoma, first remission | 1 | 0 |
| Lymphoma, second or later remission | 2 | 1 |
| Early disease† | ||
| No. | 59 | 61 (P = .2) |
| % | 67 | 77 |
| Follow-up period (mo) | ||
| Median | 87 | 83 |
| Range | 20-111 | 28-104 |
| Characteristic . | Busulfan . | TBI . |
|---|---|---|
| No. of patients | 88 | 79 |
| Recipient age (yr) | ||
| Median | 35 | 34 |
| Range | 2-55 | 1-53 |
| Donor age (yr) | ||
| Median | 35 | 34 |
| Range | 4-62 | 2-68 |
| HLA-identical siblings (n) | 87 | 79 |
| HLA-identical parents (n) | 1 | 0 |
| Marrow cell dose (×107/kg) | ||
| Median | 26 | 26 |
| Range | 3-57 | 3-58 |
| Diagnosis (n) | ||
| AML | ||
| First remission | 25 | 26 |
| Second or later remission, early relapse* | 12 | 6 |
| ALL | ||
| First remission | 11 | 11 |
| Second or later remission | 7 | 9 |
| CML | ||
| First chronic phase | 22 | 24 |
| Second, accelerated phase | 7 | 2 |
| Blast crisis | 1 | 1 |
| Lymphoma, first remission | 1 | 0 |
| Lymphoma, second or later remission | 2 | 1 |
| Early disease† | ||
| No. | 59 | 61 (P = .2) |
| % | 67 | 77 |
| Follow-up period (mo) | ||
| Median | 87 | 83 |
| Range | 20-111 | 28-104 |